Antitumor activity of naratuximab emtansine in lymphoma cell lines
| . | No. . | Median IC50, pM . | 95% confidence interval . |
|---|---|---|---|
| B-cell lymphomas | 46 | 450 | 150-800 |
| T-cell lymphomas | 8 | 22 500 | 13 000-40 000 |
| ABC-DLBCL | 7 | 600 | 81-12 800 |
| GCB-DLBCL | 20 | 400 | 56-14 651 |
| MCL | 10 | 275 | 18-794 |
| MZL | 6 | 325 | 24-18 078 |
| CLL | 2 | 13 500 | 12 000-15 000∗ |
| PMBCL | 1 | 700 | n.a. |
| ALCL | 5 | 30 000 | 15 000-40 000∗ |
| SS | 2 | 14 000 | 13 000-15 000∗ |
| PTCL-NOS | 1 | 10 000 | n.a. |
| . | No. . | Median IC50, pM . | 95% confidence interval . |
|---|---|---|---|
| B-cell lymphomas | 46 | 450 | 150-800 |
| T-cell lymphomas | 8 | 22 500 | 13 000-40 000 |
| ABC-DLBCL | 7 | 600 | 81-12 800 |
| GCB-DLBCL | 20 | 400 | 56-14 651 |
| MCL | 10 | 275 | 18-794 |
| MZL | 6 | 325 | 24-18 078 |
| CLL | 2 | 13 500 | 12 000-15 000∗ |
| PMBCL | 1 | 700 | n.a. |
| ALCL | 5 | 30 000 | 15 000-40 000∗ |
| SS | 2 | 14 000 | 13 000-15 000∗ |
| PTCL-NOS | 1 | 10 000 | n.a. |
IC50 values were obtained after 72-hour treatment.
ALCL, anaplastic large-cell lymphoma; MZL, marginal zone lymphoma; n.a., not available; PMBCL, primary mediastinal large B-cell lymphoma; PTCL-NOS, peripheral T-cell lymphoma not otherwise specified; SS, Sezary syndrome.
The upper confidence limit is held at a maximum of samples.